Abstract
Assessment of the immunogenicity and safety of marketed vaccines for COVID-19 after regular schedule and adapted vaccine schedules and routes: BNT162b2 (Comirnaty®; Pfizer-BioNTech), mRNA-1273 Vaccine (COVID-19 Vaccine Moderna®; Moderna) and COVID-19 Vaccine (ChAdOx1-S [recombinant]) (Vaxzevria®, AstraZeneca).
A A prospective, post marketing, randomized, partially single blind, multicenter, interventional study in 560 healthy adults 18-55y
Most important exclusion criteria:
• Confirmed previous covid-19-infection
• Previous covid-19 vaccination
Study will be carried out in 4 study centres, specialised in vaccination trials, in Belgium.
Intervention: Vaccines:
• BNT162b2: 30 mcg (IM), 20 mcg (IM) and 6mcg (ID)
• mRNA-1273 Vaccine : 100mcg (IM) and 50mc (IM)
• COVID-19 Vaccine (ChAdOx1-S [recombinant])
Researcher(s)
Research team(s)
Project type(s)